Philippines (FDA), Brazil (Albert Einstein), Macleod (India) all have seen the U.S. CD10 & CD12 trial results...and clearly see what the FDA refuses to...that Leronlimab has great potential to serve in the fight against COVID-19 for the sickest patients.

I tend to agree with you #EvilRabbit...I do not see this letter from the FDA taking them off course from impartially testing and reviewing the effectiveness of Leronlimab in Covid-19. i.e. FDA's position on Leronlimab in today's letter is nothing new to them.

I tend to believe that the FDA have themselves in a corner with Leronlimab with: their own protocols; reliance on P values; turning down the "4 Dose" protocol at the outset (and perhaps for CD18); failure to disclose today that Cytodyn has filed a follow-up study based upon the learnings (Age, 4 Dose...), failure to see in the interim review or request to see the interim CD-12 results (and missed or did not see the age imbalance).

I firmly believe in the science of Leronlimab, the data & the lives saved. Cytodyn has great momentum elsewhere and this defensive play by the FDA will be seen for what it is soon enough.

GLTA


GLTA